Company: Hemera Biosciences
Job title: Founder & Chief Executive Officer
Adam Rogers is the CEO and co-founder of Hemera Biosciences, a Waltham, MA ocular gene therapy company. The mission is to provide an affordable, intravitreal gene therapy administered as a one-time injection in an office setting for patients with early onset dry AMD to preserve vision and maintain quality of life. Hemera has fully enrolled to phase 1 clinical trials and will be initiating a phase 2 dry AMD study in Q2 2020.
Intravitreal HMR59 (AAVCAGsCD59) for the treatment of Age-related Macular Degeneration (AMD) 4:00 pm
HMR59 is an AAV2 gene therapy administered as intravitreal injection in an office setting Soluble CD59 (sCD59) is the transgene product and blocks complement at membrane attack complex (MAC) Two phase 1 trials have enrolled 42 subjects with doses up to 1.071x1012vg HMR-1001 evaluated 17 subjects with advanced dry AMD with 24 months follow-up HMR-1002…Read more
day: Day Two